Other languages Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 24/05/2024 am IST			5-day change	1st Jan Change
5.95 ^CNY	-3.41%		-6.74%	-44.81%

29/04	Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/04	Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study	19/03
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN	22/02
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	07/02
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.	06/02
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU	29/01
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization	09/01
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit	09/01
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China	12/23/12
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting	07/23/07
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint	20/23/20
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization	22/23/22
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	17/23/17
Hong Kong Department of Health Approves the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System	15/23/15
Asieris Pharmaceuticals Confirms Hexvix Phase III Clinical Trial in China Meet Endpoint	11/23/11
Asieris Pharmaceuticals Announces Positive Phase III Bridging Trial of Hexvix(R), a Diagnostic Drug for Bladder Cancer	11/23/11
Asieris Pharmaceuticals Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China	06/23/06
Asieris' Progress in MIBC Receives Renewed Attention with Its Inclusion in Asco 2023	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jiangsu Yahong Meditech Co., Ltd.

Equities

688176

CNE100005XW0

Other languages

Filters